PTD802

PTD802 is a novel, first-in-class small molecule therapeutic developed by Pheno Therapeutics for the treatment of neurological diseases characterized by demyelination, with an initial focus on multiple sclerosis (MS). It acts as a selective antagonist of G protein-coupled receptor 17 (GPR17), which plays a key role in regulating the maturation of oligodendrocyte precursor cells (OPCs) into myelin-producing oligodendrocytes. By inhibiting GPR17, PTD802 is designed to promote remyelination—the repair and restoration of damaged or lost myelin sheaths around nerve fibers—offering a neuroprotective approach distinct from current MS therapies that primarily target immune modulation. The drug is administered orally and has received clinical trial authorization for Phase 1 studies in healthy volunteers. Developed under an exclusive worldwide license agreement with UCB, PTD802 represents a promising strategy to address unmet needs in MS and potentially other demyelinating conditions[2][3][5][6][9].